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Biosimilars have become a hot topic in the global drug
industry. These are biological products, typically recombi-
nant proteins, that are highly similar to an already approved
biologic, known as a reference product, that show no clinically
meaningful differences in safety, purity, and potency from
the reference product. Because of variability in the cell lines
utilized, culture conditions, and other factors that different
manufacturers use to generate recombinant biological
products, these new biologics are termed biosimilars. They
are not the same as generic drugs, which is the term used
when a drug is a synthesized chemical compound [1].
A major impetus for the development of biosimilars has
been the promise of reduced costs for biologics, which
contribute signiﬁcantly to the overall high cost of oncology
care. The European Union (EU) has led the way in clinical
implementation of biosimilars. In 2008, the European Med-
icines Agency licensed the ﬁrst biosimilar recombinant hu-
man granulocyte colonyestimulating factor (G-CSF). Since
then, 5 additional biosimilar G-CSF products have been
licensed for use in the EU [2]. Approval of biosimilars in the
United States has lagged behind. The Biologics Price
Competition and Innovation Act, a provision of the 2010
Affordable Care Act, authorized approval of biosimilars
through an abbreviated pathway using data from the original
producer’s reference product [3]. As of September 2015, the
Food and Drug Administration (FDA) has approved of only 1
biosimilar product.
In the United States, ﬁlgrastim (Neupogen; Amgen,
Thousand Oaks, CA) is the sole recombinant human G-CSF
that is approved by the FDA for both mobilization of autol-
ogous peripheral blood stem cells (PBSC) and for acceleration
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(ASCT). Another recombinant human G-CSFdtbo-ﬁlgrastim
(Granix, XM02; Teva, Petach Tikva, Israel)dwas approved by
the FDA in 2012 and became commercially available in late
2013. However, because of the lack of a biosimilar pathway at
the time FDA approval was sought, tbo-ﬁlgrastim went
through the standard Biologics Licensing Application
pathway and was approved as a separate entity. Although
ﬁlgrastim and tbo-ﬁlgrastim are both nonglycosylated short-
acting recombinant human G-CSFs with similar pharmaco-
kinetic proﬁles, tbo-ﬁlgrastim is not FDA approved for either
mobilization or acceleration of engraftment after ASCT. Its
only current FDA-approved indication is for prevention of
chemotherapy-induced neutropenia in patients with non-
myeloid malignancies. FDA approval of tbo-ﬁlgrastim for this
indication was based on ﬁndings from a phase 3 clinical trial
of patients receiving myelosuppressive chemotherapy for
breast cancer. Safety data came from additional phase 3
studies in patients receiving myelosuppressive chemo-
therapy for lung cancer and non-Hodgkin lymphoma [4-7].
In this issue, Elayan and colleagues compare outcomes
and costs associated with the use of ﬁlgrastim and tbo-
ﬁlgrastim for PBSC mobilization and acceleration of count
recovery after ASCT [8]. They report the results of a single-
institution retrospective analysis of 185 patients with
lymphoma or a plasma cell disorder who received either
ﬁlgrastim or tbo-ﬁlgrastim for both mobilization and accel-
eration of engraftment after ASCT, and they show equal
efﬁcacy of the 2 agents. Patients with lymphoma received a
conditioning regimen consisting of BEAM (carmustine
[BiCNU], etoposide, cytarabine, melphalan) with or without
rituximab, whereas all patients with plasma cell disorders
received high-dose melphalan, with the exception of 1 pa-
tient, who received busulfan plus melphalan. The ﬁlgrastim
cohort was comprised of successive patients undergoing
PBSC collection and ASCT in the 18-month period immedi-
ately preceding replacement of ﬁlgrastimwith tbo-ﬁlgrastim
in the institutional formulary. All patients received stan-
dardized supportive care with identical transfusion param-
eters for red blood cells and platelets and initiation of
prophylactic antibiotics on day -1. No differences were
observed in total CD34þ cells/kg collected, peripheral CD34þ
cells/mL on days 4 and 5 of mobilization, utilization of pler-
ixafor duringmobilization, andmean collection days to reach
a target of 5 million CD34þ cells/kg. Additionally, no
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the 2 groups in the times to neutrophil or platelet recovery.
The incidence of febrile neutropenia and length of hospital
stay were also similar in both groups. Although the mean
number of platelet transfusions was higher in the tbo-
ﬁlgrastim cohort, the median number was identical, and
differences in apheresis processing volumes between the 2
groups might have been due to differential use of the COBE
Spectra and Optia system (Terumo BCT, Lakewood, CO).
These ﬁndings largely recapitulate previously published
studies by investigators in Europe, where tbo-ﬁlgrastim is
considered a biosimilar and approved for all the same in-
dications as ﬁlgrastim [9-11]. The major limitations of the
study are its retrospective nature and inadequate sample size
for detecting true statistical differences between the groups.
The most signiﬁcant ﬁnding of this study is the cost sav-
ings associated with the use of tbo-ﬁlgrastim. A savings
beneﬁt of approximately $1405 per patientd$964 for
mobilization and $441 for engraftmentdwas calculated for
patients receiving tbo-ﬁlgrastim based on the average
wholesale price of each G-CSF. This would translate to a cost
savings of nearly $260,000 if the entire group of patients in
this study received tbo-ﬁlgrastim.
Despite these savings, future use of tbo-ﬁlgrastim in the
transplantation setting is likely to be stymied by the com-
mercial availability earlier this month of yet another re-
combinant human G-CSF, ﬁlgrastim-sndz, which is the only
current FDA-approved biosimilar. Filgrastim-sndz received
FDA approval earlier this year for all 5 indications for which
ﬁlgrastim is approved, including the ASCT setting for PBSC
mobilization and acceleration of count recovery.
As the 12-year marketing exclusivity period ends for
many biologics, we are likely to see a surge in production
and approval of biosimilars in the United States. Many
challenges, including cost savings, remain a concern with
the introduction of biosimilars. Although generic small-
molecule drugs have saved US consumers nearly $1.5 tril-
lion in the past decade, cost savings with biologics will
inherently be more limited because of their complexity [12].
In the EU, the 19 available biosimilars cost on average 20% to
25% less than their reference counterparts [13]. A similar
trend for pricing of biosimilars is expected in the United
States; in fact, initial pricing of ﬁlgrastim-sndz indicates a
cost savings of only 16%. Vigorous pharmacovigilance of
biosimilars after approval will be critical to ensuring the
safety proﬁle of each new biologic. The increased
complexity of recombinant biological products due to pro-
tein folding confers a higher immunogenic potential for
biosimilars compared with small-molecule drugs. The
importance of rigorous safety monitoring is best illustrated
by the development of antibody-mediated pure red cell
aplasia in some patients in Europe receiving epoietin alfa
(Eprex; Johnson & Johnson, Manati, Puerto Rico) that was
associated with a manufacturing change that increased the
immunogenicity of epoietin alfa [14].The lack of a standardized naming convention for bio-
similars may also pose a challenge, particularly with respect
to traceability as part of postmarketing surveillance. The FDA
has proposed a plan to attach a unique 4-letter sufﬁx to
biosimilars to indicate the brand they copy (eg, -sndz for the
Sandoz ﬁlgrastim biosimilar). How biosimilars are used and
for which clinical applications will ultimately require more
clinical experience with individual biologics as they become
available.
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